Woodline Partners LP Amryt Pharma PLC Transaction History

Woodline Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$6.68 - $7.58 $9,612 - $10,907	-1,439 Reduced 0.5%	286,543 $2.09 Million
Q3 2022 Nov 14, 2022	SELL	$6.8 - $8.01 $260,644 - $307,023	-38,330 Reduced 11.75%	287,982 $1.99 Million
Q2 2022 Aug 15, 2022	SELL	$6.85 - $8.87 $1.06 Million - $1.37 Million	-154,051 Reduced 32.07%	326,312 $2.28 Million
Q1 2022 May 16, 2022	BUY	$6.3 - $10.86 $2.19 Million - $3.78 Million	347,925 Added 262.71%	480,363 $3.97 Million
Q4 2021 Feb 14, 2022	BUY	$9.44 - $12.24 $1.25 Million - $1.62 Million	132,438 New	132,438 $1.43 Million

142K

Ticker AMYT
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 64,177,000
Description
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with ...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.